Clinical Trials
152 trialsEvaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers
National Institutes of Health Clinical Center (CC)
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
Rigel Pharmaceuticals
JADE
iOMEDICO AG
FiREBOLT
Eli Lilly and Company
adIVO
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Astellas Pharma Inc
Intravital Microscopy in Human Solid Tumors
Mayo Clinic
Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
National Institutes of Health Clinical Center (CC)
Trop2-targeted immunoPET Imaging of Solid Tumors
RenJi Hospital
Safety and Efficacy of CD160-Enhanced Autologous Antigen-Specific T-Cells (BTC-Ag-T) in Advanced Biliary Tract Cancer
Shanghai Zhongshan Hospital
FOENIX-CCA4
Taiho Oncology, Inc.
TRACK
TargetCancer Foundation
Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors
Myeloid Therapeutics
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
National Institutes of Health Clinical Center (CC)
SEVILLA
UNICANCER
To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
Shenzhen Xinhe Biomedical
BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
Bold Therapeutics, Inc.
Pemigatinib + Afatinib in Advanced Refractory Solid Tumors
Massachusetts General Hospital
The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.
New Phase Ltd.
Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma
Genfit
A Study of PHST001 in Advanced Solid Tumors
Pheast Therapeutics
Beacon-BTC
J-Pharma Co., Ltd.
18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
Peking University First Hospital
Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma
Mayo Clinic
ELEGANCE
Nantes University Hospital
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Kestrel Therapeutics, Inc.
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
Jazz Pharmaceuticals
A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement
Hoosier Cancer Research Network
Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)
Australasian Gastro-Intestinal Trials Group
Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic Cholangiocarcinoma
Shanghai Zhongshan Hospital
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
National Institutes of Health Clinical Center (CC)
Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma
Shandong Cancer Hospital and Institute
FAPDIG
University Hospital, Bordeaux
Map HPB
University of Nottingham
A Study of MGC028 in Participants With Advanced Solid Tumors
MacroGenics
Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery
Memorial Sloan Kettering Cancer Center
Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio
Beth Israel Deaconess Medical Center
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Tango Therapeutics, Inc.
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
Mayo Clinic
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Pliant Therapeutics, Inc.
Molecular Epidemiology of Biliary Tree Cancers
M.D. Anderson Cancer Center
A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma
M.D. Anderson Cancer Center
LASER
Seoul National University Hospital
ANTARES
Instituto do Cancer do Estado de São Paulo
RIS-TH
Assistance Publique - Hôpitaux de Paris
ELUCIDATE
City of Hope Medical Center
Liver Transplantation in Intrahepatic Cholangiocarcinoma
Rutgers, The State University of New Jersey
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
Alentis Therapeutics AG
Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab
CHA University
CHOC
University Hospital, Angers